Clinical Trial Update: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 randomized dose-ranging study evaluated the efficacy of tralokinumab in adults with idiopathic pulmonary fibrosis; the trial was terminated, and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Tralokinumab (tralokinumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2017-05-15